Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Patents and Intangibles - Additional Information (Detail)

v3.19.3
Acquisition of Patents and Intangibles - Additional Information (Detail) - USD ($)
 3 Months Ended
Oct. 16, 2012
Aug. 31, 2019
Aug. 31, 2018
May 31, 2019
Acquired Finite-Lived Intangible Assets [Line Items]        
Intangible asset acquired gross   $ 3,500,000    
Estimated aggregate future amortization expense in next twelve months   2,000,000    
Estimated aggregate future amortization expense in year two   2,000,000    
Estimated aggregate future amortization expense in year three   1,500,000    
Estimated aggregate future amortization expense in year four   1,100,000    
Estimated aggregate future amortization expense in year five   $ 1,000,000    
Issuance of common stock shares   383,584,367   329,554,763
Common stock per shares   $ 0.001   $ 0.001
ProstaGene, LLC        
Acquired Finite-Lived Intangible Assets [Line Items]        
Acquisition of ProstaGene LLC, value   $ 11,558,000    
Issuance of common stock shares   20,278,000    
Common stock per shares   $ 0.57    
ProstaGene, LLC | Dr .Pestell | Stock Restriction Agreement        
Acquired Finite-Lived Intangible Assets [Line Items]        
Restricted common stock, shares   8,342,000    
Common stock shares restriction period   3 years    
Stock repurchase price, per share   $ 0.001    
ProstaGene, LLC | Investment Advisory, Management and Administrative Service        
Acquired Finite-Lived Intangible Assets [Line Items]        
Investment earned shares   1,620,000    
Patents        
Acquired Finite-Lived Intangible Assets [Line Items]        
Asset purchase, cash paid $ 3,500,000      
Estimated useful life of acquired asset   10 years    
Amortization expense related to acquired patents   $ 528,400 $ 87,500